Current Affairs - Miscellaneous - Discussion

The U.S. Food and Drug Administration (FDA) approved the first vaccine for chikungunya on November 10, 2023. The vaccine, called VLA1553, was developed by Valneva Austria, a subsidiary of the French company Valneva. The vaccine is intended for adults 18 years of age and older who are at increased risk of exposure to chikungunya. This includes people who live in or travel to areas where the virus is common, as well as people who work with chikungunya-infected animals.